These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26896000)

  • 1. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.
    Mego M; Cholujova D; Minarik G; Sedlackova T; Gronesova P; Karaba M; Benca J; Cingelova S; Cierna Z; Manasova D; Pindak D; Sufliarsky J; Cristofanilli M; Reuben JM; Mardiak J
    BMC Cancer; 2016 Feb; 16():127. PubMed ID: 26896000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
    Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
    Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
    Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SDF-1/CXCR4-induced epithelial-mesenchymal transition by kisspeptin-10.
    Gründker C; Bauerschmitz G; Knapp J; Schmidt E; Olbrich T; Emons G
    Breast Cancer Res Treat; 2015 Jul; 152(1):41-50. PubMed ID: 26062751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
    Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
    Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
    Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
    Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients.
    Mego M; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Luha J; Gronesova P; Pindak D; Fridrichova I; Celec P; Reuben JM; Cristofanilli M; Mardiak J
    Breast J; 2015; 21(2):155-60. PubMed ID: 25623304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.
    Markiewicz A; Książkiewicz M; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Szade J; Żaczek AJ
    PLoS One; 2014; 9(4):e93901. PubMed ID: 24709997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
    Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
    In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
    Bystricky B; Jurisova S; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Manasova D; Gronesova P; Pindak D; Mardiak J; Celec P; Mego M
    Anticancer Res; 2017 Apr; 37(4):1787-1791. PubMed ID: 28373442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
    Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Circulating Tumour Cells on Production of IL-1α, IL-1β and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment.
    Vilsmaier T; Rack B; König A; Friese K; Janni W; Jeschke U; Weissenbacher T;
    Anticancer Res; 2016 Oct; 36(10):5227-5236. PubMed ID: 27798883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis.
    Ejaeidi AA; Craft BS; Puneky LV; Lewis RE; Cruse JM
    Exp Mol Pathol; 2015 Aug; 99(1):163-72. PubMed ID: 26079660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
    Mego M; Mani SA; Lee BN; Li C; Evans KW; Cohen EN; Gao H; Jackson SA; Giordano A; Hortobagyi GN; Cristofanilli M; Lucci A; Reuben JM
    Int J Cancer; 2012 Feb; 130(4):808-16. PubMed ID: 21387303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.